Table 4.
Recommended range margins for all site investigated (except for medulloblastoma-spine fields) considering R50 and R90. Also shown are the uncertainties based on dose calculation alone.
| Site | RMSDR50 | RMSDR90 | ||
|---|---|---|---|---|
| Dose calc. only | Total | Dose calc. only | Total | |
| Liver + prostate | 1.0% | 2.6% + 1.2 mm | 1.4% | 2.8% + 1.2 mm |
| Whole brain | 1.7% | 3.0% + 1.2 mm | 2.0% | 3.1% + 1.2 mm |
| Lung + breast | 3.2% | 4.0% + 1.2 mm | 5.3% | 5.9% + 1.2 mm |
| Head & neck | 3.0% | 3.8% + 1.2 mm | 6.0% | 6.5% + 1.2 mm |
| Lung + breast + head & neck | 3.0% | 3.9% + 1.2 mm | 5.8% | 6.3% + 1.2 mm |